表紙
市場調査レポート

アデホビルの中国市場の分析

Investigation Report on China Adefovir Market, 2010-2019

発行 China Research and Intelligence 商品コード 334092
出版日 ページ情報 英文 35 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
アデホビルの中国市場の分析 Investigation Report on China Adefovir Market, 2010-2019
出版日: 2015年07月02日 ページ情報: 英文 35 Pages
概要

中国国内では現在、B型肝炎表面抗原 (HBsAg:HBs抗原) が原因で無くなる人々の比率は低下していますが、人口ベースが巨大なため、B型肝炎の患者数は9000万人、慢性B型肝炎 (CHB) の患者数は2000万人、といずれも高水準に達しています。アデホビルは、CHBの治療薬であるヌクレオチド類似体の一種で、中国国内で現在急速に市場規模が成長しています。2005年には約1000億人民元だった売上高は、60%程度の年平均成長率 (CAGR) で拡大し、2014年には4億人民元に達しました。

当レポートでは、中国におけるアデホビルの市場について分析し、全体的な市場規模の動向(過去5年間分)や国内価格の動向、企業別・投薬形態別の市場シェア、主要メーカーのプロファイル、将来的な市場動向の見通し(今後5年間分)などを調査・推計しております。

第1章 アデホビルの関連概念

  • 症状
  • 世界市場での販売状況

第2章 中国のアデホビル市場の概況

  • 中国国内でのアデホビルの特許出願・認証状況
  • 主要メーカー
  • 市場規模

第3章 アデホビルの販売状況の分析 (過去5年間分)

  • 販売額
    • 全体的な販売額
    • 地域別の販売額
  • 販売量
    • 全体的な販売量
    • 地域別の販売量

第4章 中国のアデホビル市場:主要メーカーの市場シェアの分析 (過去5年間分)

  • 市場シェア (販売額ベース)
  • 市場シェア (販売量ベース)

第5章 中国のアデホビル市場:剤形別の分析 (過去5年間分)

  • 剤形別の市場シェア (販売額ベース)
  • 剤形別の市場シェア (販売量ベース)

第6章 アデホビルの病院向け基準価格

  • YSY (Shanghai) Pharmaceutical Co., Ltd
  • TIPR Pharmaceutical Responsible Co., Ltd (商標名:Daiding)
  • Qilu Pharmaceutical Co., Ltd (商標名:Yilaifen)
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd (商標名:Mingzheng)
  • United Laboratories (商標名:Adixian)
  • Fujian Cosunter Pharmaceutical Co., Ltd (商標名:Aganding)
  • GlaxoSmithKline (Tianjin) Co., Ltd (商標名:Hepsera)

第7章 中国国内のアデホビルの主要メーカー (過去5年間分)

  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd
  • TIPR Pharmaceutical Responsible Co., Ltd
  • United Laboratories
  • Fujian Cosunter Pharmaceutical Co., Ltd
  • GlaxoSmithKline (Tianjin) Co., Ltd

第8章 中国のアデホビル市場の将来展望 (今後5年間分)

  • 市場規模の予測
  • 競争環境の見通し

図表一覧

目次
Product Code: 1507253

In Mar. 2015, WHO issued Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection, indicating that 2 billion people around the world had or are having HBV infection and that about 240 million people are infected with chronic hepatitis B virus (HBV), among which 0.65 million die of hepatitis B-related diseases. Hepatitis B surface antigen (HBsAg ) rate among people aged below 60 has fallen from 9.75% a decade ago to 7.18% now. However, since China has a large population base, the number of people infected with chronic HBV is calculated to be over 90 million and the number of chronic hepatitis B (CHB) patients is 20 million. Hence, the severe status of diagnosis and treatment of CHB. So far, chronic and viral hepatitis B has become one of the major threats to human health and CHB has already become the ninth leading cause of death.

Nucleotide analog, the leading antiviral product for the treatment of CHB, has such main varieties as entecavir, adefovir dipivoxil, lamivudine, telbivudine, emtricitabine and tenofovir disoproxil in the clinic.

In 2002, GlaxoSmithKline (GSK) acquired the franchise rights to market adefovir dipivoxil, the anti-hepatitis B drug of Gilead Sciences, Inc. in mainland China, Japan, Korea and Taiwan under the trade name of Hepsera. In 2013, the global sales value of Hepsera was down by 23.81%. In 2005, adefovir dipivoxil made by GSK was first approved to enter China under the trade name of Hepsera.

Adefovir develops fast after entering China, annual sales value rising from about CNY 10 million in 2005 to CNY 400 million in 2013 and CAGR reaching nearly 60% during the period of 2005-2014. GlaxoSmithKline (Tianjin) Co., Ltd, United Laboratories, Fujian Cosunter Pharmaceutical Co., Ltd and Chia Tai Tianqing Pharmaceutical Group Co., Ltd occupy the majority of the Chinese market, among which GlaxoSmithKline (Tianjin) Co., Ltd had the largest market share of about 43% for sales value in 2014.

With the large amounts of hepatitis B patients in China, the market size of adefovir is expected to keep growing in the next few years.

Readers can get at least the following information from this report:

  • market size of adefovir in China
  • competitive landscape of adefovir in Chinese market
  • price of adefovir made by different enterprises in China
  • market outlook of adefovir in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-hepatitis drugs
  • investors/ research institutions interested in Chinese medicine market
  • any interest in the Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Adefovir

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Adefovir in China

  • 2.1. Patent and Approval Status of Adefovir in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Sales Status of Adefovir in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Manufacturers of Adefovir in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Adefovir in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Adefovir in Chinese Hospitals in 2014

  • 6.1. YSY (Shanghai) Pharmaceutical Co., Ltd
  • 6.2. TIPR Pharmaceutical Responsible Co., Ltd (Trade Name: Daiding)
  • 6.3. Qilu Pharmaceutical Co., Ltd (Trade Name: Yilaifen)
  • 6.4. Chia Tai Tianqing Pharmaceutical Group Co., Ltd (Trade Name: Mingzheng)
  • 6.5. United Laboratories (Trade Name: Adixian)
  • 6.6. Fujian Cosunter Pharmaceutical Co., Ltd (Trade Name: Aganding)
  • 6.7. GlaxoSmithKline (Tianjin) Co., Ltd (Trade Name: Hepsera)

7. Major Manufacturers of Adefovir in Chinese Market, 2010-2014

  • 7.1. Chia Tai Tianqing Pharmaceutical Group Co., Ltd
  • 7.2. TIPR Pharmaceutical Responsible Co., Ltd
  • 7.3. United Laboratories
  • 7.4. Fujian Cosunter Pharmaceutical Co., Ltd
  • 7.5. GlaxoSmithKline (Tianjin) Co., Ltd

8. Market Outlook of Adefovir in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Patent Status of Adefovir in China
  • Chart Approval Information of Adefovir in China
  • Chart Sales Status of Adefovir in China
  • Chart Sales Value of Adefovir in China, 2010-2014
  • Chart Sales Value of Adefovir in Some Regions in China, 2010-2014
  • Chart Sales Volume of Adefovir in China, 2010-2014
  • Chart Market Share of TOP3 Manufacturers of Adefovir for Sales Value in China, 2010-2014
  • Chart Sales Value and Market Share of Adefovir Made by GlaxoSmithKline (Tianjin)in China, 2010-2014
  • Chart Sales Value and Market Share of Adefovir Made by Chia Tai Tianqing in China, 2010-2014
  • Chart Sales Value and Market Share of Adefovir Made by TIPR in China, 2010-2014
  • Chart Sales Value and Market Share of Adefovir Tablets in China, 2010-2014
  • Chart Sales Value and Market Share of Adefovir Capsules in China, 2010-2014
  • Chart Price of Adefovir Made by YSY (Shanghai) Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Adefovir Made by TIPR Pharmaceutical Responsible Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Adefovir Made by Qilu Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Adefovir Made by Chia Tai Tianqing Pharmaceutical Group Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Adefovir Made by United Laboratories in Some Chinese Cities in 2014
  • Chart Price of Adefovir Made by Fujian Cosunter Pharmaceutical Co., Ltd in Some Chinese Cities in 2014
  • Chart Price of Adefovir Made by GlaxoSmithKline (Tianjin) Co., Ltd in Some Chinese Cities in 2014
Back to Top